AstraZeneca's Brilinta wins in diabetic artery disease patients - FiercePharma

AstraZeneca's Brilinta wins in diabetic artery disease patients  FiercePharma

AstraZeneca's Brilinta has a checkered history when it comes to racking up data in new patient pools. But the drug has emerged victorious from its latest test.